ETFs BioCryst Pharmaceuticals, Inc.

BCRX

US09058V1035

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 22:34:50 30/10/2026 +03			5-day change	1st Jan Change
8.455 ^USD	-0.76%		+10.20%	+8.08%

10-29	Biocryst Pharmaceuticals, Inc. Presents New Data for Orladeyo and Navenibart At the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting	CI
10-21	BioCryst Pharmaceuticals Pellet Form of Hereditary Angioedema Treatment Approved by US FDA	MT

ETFs positioned on BioCryst Pharmaceuticals, Inc.

Name	YTD change	Weight	AuM
FIRST TRUST SMALL CAP CORE ALPHADEX FUND ETF - USD	+21.64%	-	1,411 M€
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	+4.12%	-	37 M€
SCHWAB U.S. BROAD MARKET ETF - USD	+10.29%	-	44,934 M€
INVESCO DYNAMIC BIOTECHNOLOGY & GENOME ETF - USD	+24.52%	3.26%	379 M€
VIRTUS LIFESCI BIOTECH PRODUCTS ETF - USD	+29.71%	1.87%	107 M€
ALPS MEDICAL BREAKTHROUGHS ETF - USD	+6.25%	0.82%	222 M€
SIMPLIFY PIPER SANDLER US SMALL-CAP PLUS INCOME ETF - USD	+14.95%	0.75%	7 M€
STATE STREET SPDR S&P BIOTECH ETF - USD	+26.92%	0.69%	10,676 M€
GLOBAL X S&P BIOTECH ETF - AUD	+22.92%	0.6%	35 M€
INVESCO NASDAQ FUTURE GEN 200 ETF - USD	+15.27%	0.38%	23 M€
ISHARES HEALTHCARE INNOVATION UCITS ETF - USD	+26.92%	0.19%	1,260 M€
GOLDMAN SACHS ACTIVEBETA U.S. SMALL CAP EQUITY ETF - USD	+14.98%	0.18%	1,095 M€
FRANKLIN U.S. SMALL CAP MULTIFACTOR INDEX ETF - USD	+13.49%	0.17%	53 M€
ISHARES U.S. SMALL-CAP EQUITY FACTOR ETF - USD	+13.31%	0.17%	4,317 M€
MCELHENNY SHEFFIELD MANAGED RISK ETF - USD	+1.67%	0.14%	186 M€
ISHARES BIOTECHNOLOGY ETF - USD	+28.32%	0.13%	9,953 M€
ISHARES NASDAQ US BIOTECHNOLOGY UCITS ETF - USD	+28.50%	0.12%	1,079 M€
ISHARES NASDAQ US BIOTECHNOLOGY UCITS ETF (D) - USD	+28.57%	0.12%	78 M€
INVESCO NASDAQ BIOTECHNOLOGY ETF - USD	+26.81%	0.12%	81 M€
VANGUARD RUSSELL 2000 GROWTH ETF - USD	+8.26%	0.12%	1,568 M€
ISHARES RUSSELL 2000 GROWTH ETF - USD	+8.26%	0.11%	15,028 M€
FIDELITY ENHANCED SMALL CAP ETF - USD	+19.71%	0.09%	6,480 M€
JPMORGAN BETABUILDERS U.S. SMALL CAP EQUITY ETF - USD	+14.53%	0.09%	732 M€
FIRST TRUST MULTI CAP GROWTH ALPHADEX FUND ETF - USD	+8.48%	0.08%	608 M€
INNOVATOR U.S. SMALL CAP MANAGED FLOOR ETF - USD	+11.61%	0.07%	94 M€
STATE STREET SPDR RUSSELL 2000 U.S. SMALL CAP UCITS ETF - USD	+13.67%	0.07%	5,739 M€
ISHARES U.S. SMALL CAP INDEX ETF (CAD-HEDGED) - CAD	+11.32%	0.07%	520 M€
GLOBAL X RUSSELL 2000 COVERED CALL ETF - USD	-0.20%	0.07%	1,395 M€
L&G RUSSELL 2000 US SMALL CAP QUALITY UCITS ETF - USD	+22.07%	0.06%	225 M€
ISHARES MORNINGSTAR SMALL-CAP GROWTH ETF - USD	+9.75%	0.06%	1,019 M€
XTRACKERS MSCI GLOBAL SDG 3 GOOD HEALTH UCITS ETF 1C - USD	+18.15%	0.06%	28 M€
GLOBAL X RUSSELL 2000 COVERED CALL & GROWTH ETF - USD	+6.59%	0.06%	9 M€
GLOBAL X RUSSELL 2000 ETF - USD	+12.57%	0.06%	1,540 M€
ISHARES RUSSELL 2000 ETF - USD	+12.87%	0.06%	82,179 M€
INVESCO RAFI US 1500 SMALL-MID ETF - USD	+15.17%	0.06%	2,894 M€

1 2 3 4 5

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.

Employees

435

Sector

Biotechnology & Medical Research

Calendar

11-04 Earnings release - Q3 2026

More about the company